SCHEMBL65983

SCHEMBL65983

O=C(N[C@H]1CC[C@H]2CN(CCCc3ccc(F)cc3)C[C@H]21)C(C1CCCCC1)C1CCCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 6/20 0.57
KCNH2 Q12809 2/20 0.57
CCR3 P51677 1/20 0.41
KDM1A O60341 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
CNR1 P21554 3/20 0.38
CACNA1F O60840 2/20 0.38
HTR1A P08908 2/20 0.38
ADORA3 P0DMS8 2/20 0.38
DRD4 P21917 2/20 0.38
DRD5 P21918 2/20 0.38
HRH2 P25021 2/20 0.38
ADRA1D P25100 2/20 0.38
HTR2A P28223 2/20 0.38
HTR7 P34969 2/20 0.38
ADRA1A P35348 2/20 0.38
HRH1 P35367 2/20 0.38
ADRA1B P35368 2/20 0.38
OPRM1 P35372 2/20 0.38
DRD3 P35462 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL66621 0.90 CACNA1B (0.61) CACNA1BKCNH2DRD4OPRM1CHRM3
SCHEMBL66365 0.90 CACNA1B (0.67) CACNA1BKCNH2
SCHEMBL65481 0.89 CACNA1B (0.63) CACNA1BKCNH2SLC6A3DRD2GAA
SCHEMBL66633 0.89 KCNH2 (0.55) CACNA1BKCNH2CCR3CNR1CACNA1F
SCHEMBL67493 0.88 CACNA1B (0.69) CACNA1BKCNH2CCR3CNR1CNR2
SCHEMBL66793 0.87 KCNH2 (0.54) CACNA1BKCNH2CNR1CACNA1FHTR1A
SCHEMBL65634 0.87 KCNH2 (0.54) CACNA1BKCNH2CNR1CACNA1FHTR1A
SCHEMBL66301 0.86 CACNA1B (0.57) CACNA1BKCNH2
SCHEMBL66732 0.86 CACNA1B (0.57) CACNA1BKCNH2
SCHEMBL65863 0.85 CACNA1B (0.51) CACNA1BKCNH2CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129417-B2 Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers ABBOTT LABORATORIES (US) 2012-03-06 US claimed
WO-2011149995-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2011-12-01 WO claimed
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2011-11-17 US claimed
US-20100130558-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-05-27 US claimed
US-8129417-B2 Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers ABBOTT LABORATORIES (US) 2012-03-06 US disclosed
WO-2011149995-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2011-12-01 WO disclosed
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2011-11-17 US disclosed
US-20100130558-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130558-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, ORAI1, CACNA1S CACNA1B 5/4885KCNH2 24/4885CCR3 3442/4885
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, ORAI1, CACNA1S CACNA1B 5/4885KCNH2 24/4885CCR3 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.